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ity. At present, however, it remains difficult to test this receptor signaling. Finn and Whistler test the hypothe-
sis that agonist-induced trafficking of opioid receptorshypothesis in Drosophila CNS neurons.
The work of Landmesser and colleagues provides val- regulates the development of tolerance and depen-
dence. The results show that measures of toleranceuable clues about the role of NCAM at synapses and
furnishes an insightful starting point for dissecting the and withdrawal to morphine are decreased under con-
ditions where receptors are trafficked through the en-molecular events of synaptogenesis after contact be-
tween pre- and postsynaptic partners. In addition, how- docytic/recycling pathway.
ever, this work also teaches us some very important
lessons about analyzing knockout phenotypes and the Motivated by attempts to find an opioid agonist that
conclusions that can be drawn. Numerous genetic defi- could be used in the relief of pain without the develop-
ciencies of abundant and interesting molecules have ment of tolerance, the mechanisms that underlie toler-
been generated in many model systems with only limited ance and dependence to opioids have been the subject
apparent phenotype. The natural conclusion that is often of investigation for more than 50 years. The development
drawn is that the molecule was nonessential probably of tolerance to an opioid means that with regular use,
because of other redundant pathways in the system. an ever-escalating dose is required to produce an equiv-
Evolution presumably has determined what is essential, alent effect. There are two major forms of tolerance.
however, and in the case of NCAM, at the very least it One, termed associative tolerance, is closely linked with
probably helped mice (and humans presumably) main- environmental cues such that the presence of these
tain the required synaptic performance to escape preda- cues together with opioids result in a reduced effect.
tors. As linkage analysis between genome sequence The second form of tolerance, nonassociative, is linked
and human diseases becomes more complete, we are with the opioid receptor and subsequent signal trans-
all the more compelled to understand the detailed roles duction processes.
of specific molecules in cellular and organ function, even One kind of mechanism of nonassociative tolerance
if complete ablation of the gene is not too disruptive to involves direct effects on the opioid receptor, and in-
the life of a mouse in a cage, or fly in a vial. The work cludes uncoupling of the opioid receptor from signal
of Landmesser and colleagues is a good example of transduction (desensitization) and possibly a decrease
just how demanding and how rewarding this will be. in receptor number after prolonged treatment with high
doses of opioids (downregulation). A second mecha-
nism involves adaptive processes, in response to con-Timothy A. Ryan
tinued opioid signaling, that result in a change in theDepartment of Biochemistry
physiology of the cell. The adaptive response wouldWeill Medical College of Cornell University
necessarily oppose the acute action of the opioid to1300 York Ave
bring about “normal” function even in the continuedNew York, New York 10021
presence of morphine. This adaptive response is
thought to be independent of acute signaling by opioid
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showed that some agonists, like methadone, are effi-Zakharenko, S., Chang, S., O’Donoghue, M., and Popov, S.V. (1999).
J. Cell Biol. 144, 507–518. cient at causing receptor internalization whereas other
agonists, such as morphine, are not. From those initial
observations, a ratio was calculated where the relative
ability of a given agonist to activate potassium currents
(relative activity; RA) was divided by its ability to cause
receptor internalization (versus endocytosis; VE). Ago-A RAVE about Opioid Withdrawal
nists with large RA/VE numbers activated potassium
currents but were poor at triggering internalization. This
ratio, termed RA/VE, was hypothesized to determineControl of trafficking of g protein-linked receptors is




chronic agonist treatment. Agonists with high RA/VE oid receptors are internalized, however, adenylyl cy-
clase activity and CREB-mediated gene expressionvalues would activate various effectors for a prolonged
period, because of the inability to signal the endocytic were reduced. The RA/VE hypothesis was therefore sup-
ported leading to the conclusion that receptor internal-pathway, and compensatory cellular adaptations would
mediate tolerance. Agonists with low RA/VE values, on ization plays an important role in the cellular response
to chronic opioid treatment. This first direct test will, atthe other hand, would be uncoupled from effectors, re-
moved form the membrane, and no compensatory the least, motivate critical examination in the future.
How far will the RA/VE hypothesis go to help in themechanism would develop.
The paper by Finn and Whistler in this issue further understanding of opioid tolerance and withdrawal?
A paper that is particularly relevant to this questiontests the RA/VE hypothesis. By using different mutated
forms of the mu opioid receptor, the role of receptor examined the differences in opioid tolerance and
changes in receptor number following chronic treatmentinternalization in the development of tolerance and with-
drawal to opioids was examined. The effects of mor- with morphine and etorphine (Stafford et al., 2001). Etor-
phine is both a potent agonist and an efficient activatorphine and methadone were tested on three forms of the
-opioid receptor (Figure). Methadone, but not morphine, of receptor internalization so it has a RA/VE value that
is much lower than that of morphine (Whistler et al.,resulted in the endocytosis of the wild-type receptor
(WT MOR). As previously shown, a chimeric receptor 1999). Stafford et al. showed that morphine treatment
caused a decrease in the analgesic potency, an effectwhere the C terminus of the delta-opioid receptor was
substituted for the wild-type C terminus (D MOR) was that was linearly dependent on the dose. As has been
reported in other studies, there was no change in opioidinternalized and trafficked to the lysosomal pathway by
both morphine and methadone (Whistler and vonZastrow, receptor number. A very different pattern was observed
in animals treated chronically with etorphine. Little or1998). The third receptor (R MOR) was also a chimera with
the C-terminal of the delta receptor, but retained a short no tolerance developed with lower doses of etorphine,
but as the dose etorphine was increased, tolerance in-sequence of MOR1 that directs the receptor into the
endosomal compartment for recycling back to the plasma creased sharply. Interestingly, at the high doses, there
was also a 50% downregulation of receptors. The inter-membrane. Having characterized the differences in traf-
ficking of each of these receptors by both morphine and pretation based on the RA/VE hypotheses would be that
morphine treatment induced an adaptive mechanismmethadone, the effects of the two agonists were exam-
ined on the acute inhibition of adenylyl cyclase and the that resulted in tolerance. Etorphine, on the other hand,
being both a potent agonist and an efficient activator ofsuperactivation resulting from prolonged application.
Adenylyl cyclase activity was determined by measuring receptor internalization, caused little tolerance at lower
doses and at higher doses caused tolerance through awhole-cell cAMP levels, and cAMP-dependent gene ex-
pression was evaluated by a novel method where CREB- downregulation of receptors. Unfortunately, the severity
of withdrawal was not determined. The prediction basedinduced expression of a reporter protein (luciferase) was
measured. Both these assays were used as measures on the RA/VE hypothesis would be that withdrawal in the
morphine-treated animals would be substantially moreof cellular withdrawal.
The results show that when activated receptors remain severe than in the etorphine-treated animals.
Given that there are multiple downstream signals in-on the surface of the plasma membrane, there is an upreg-
ulation of adenylyl cyclase and increased gene expression duced by chronic treatment with morphine, it is possible
that treatment of cells with morphine for periods of hoursthrough CREB. This adaptive response results in cellular
tolerance and withdrawal. Under conditions where opi- (as in the present study) may not model the full complex-
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It is clear, however, that uncoupling of receptors from
effectors does not have much to do with withdrawal. Adap-
tive changes have not been observed on effectors that are
directly activated by opioids, such as inwardly rectifying
potassium or voltage-gated calcium conductances, in tis- Presenilin-1 and Memoriessues treated chronically with opioids (reviewed in Williams
of the Forebrainet al., 2001). Other cellular and pharmacological properties
invoked in the development of tolerance and dependence
include differences in intrinsic efficacy between agonists,
receptor reserve, constitutive activity of receptors, and In this issue of Neuron, Feng and colleagues (2001)
the rate of receptor recycling (Chavkin et al., 2001). report that forebrain-specific Presenilin-1 conditional
It is now critical to extend tests of the RA/VE hypothe- knockout mice show defects in enrichment-induced
sis to animal models. One relatively simple test would neurogenesis in the dentate gyrus. This defect in neu-
be to pursue the experimental protocol used by Stafford rogenesis is associated with enhanced fear memory of
et al. (2001) as described above with a range of drugs contextual cues when animals are subjected to enrich-
having different RA/VE values. This protocol could also ment between training and testing. The authors suggest
be extended to cellular studies to determine the extent that neurogenesis in the adult dentate gyrus may serve
of receptor uncoupling from effectors such as potas- to clear out old memory traces from the hippocampus,
sium and calcium conductances as well as adaptive thus leaving the hippocampus available for new mem-
responses such as the increase in cAMP-dependent ory processing.
transmitter release (Chieng and Williams, 1998; Ingram
et al., 1998). A second approach is to develop animals Genetic studies of rare cases of early-onset familial Alz-
with the mutant receptors constructed by Finn and heimer’s disease (FAD) have provided important clues
Whistler. The outcome of these studies may ultimately into the etiology of the disease. In particular, these stud-
support or disprove the RA/VE hypothesis, but will surely ies have identified missense mutations in the gene en-
further the understanding of the mechanisms responsi- coding amyloid precursor protein (APP), as well as in
ble for tolerance and dependence to opioids. the genes encoding presenilin-1 (PS1) and the related
presenilin-2 (PS2). These mutations share the common
feature that they alter the -secretase cleavage of APPVeronica Alvarez,1 Seksiri Arttamangkul,2
and John T. Williams3 to increase the production of the amyloidogenic A42,
a primary component of amyloid plaques in both familial1 Department of Neurobiology
Harvard Medical School and sporadic AD. Recent studies have now strongly
suggested that the presenilins function as the activeBoston, Massachusetts 02115
2 Physiology and Pharmacology site components of -secretases, and have focused at-
tention on the presenilins as potential targets of prote-Oregon Health Sciences University
Portland, Oregon 97201 ase inhibitor therapy for the treatment of AD (for recent
reviews, see Selkoe, 2001; Tanzi and Bertram, 2001).3 Vollum Institute
